financetom
Business
financetom
/
Business
/
Full Circle Lithium Sales of Lithium-ion Battery Firefighting Agent Pass US$300,000
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Full Circle Lithium Sales of Lithium-ion Battery Firefighting Agent Pass US$300,000
Nov 11, 2024 5:52 AM

08:28 AM EST, 11/11/2024 (MT Newswires) -- Full Circle Lithium ( FCLIF ) , a U.S.-based lithium-products manufacturer, on Monday said that sales of FCL-X, the company's lithium-ion battery fire-extinguishing agent, has surpassed US$300,000.

"We are very pleased to see that we achieved meaningful non-recurring sales of FCL-X in all product lines in the past few weeks even though we have just begun our marketing and sales efforts, including signing up with US specialty fire safety distributor AEST Fire & Safety," said CEO Carlos Vicens.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Advance Pre-Bell Monday
Sector Update: Consumer Stocks Advance Pre-Bell Monday
Dec 16, 2024
09:06 AM EST, 12/16/2024 (MT Newswires) -- Consumer shares were advancing pre-bell Monday with the Consumer Staples Select Sector SPDR Fund ( XLP ) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) 0.4% higher recently. Alibaba Group Holding ( BABA ) is nearing an agreement to sell its department store business Intime to Youngor Fashion...
Viridian Therapeutics Meets Endpoints in Late-Stage Veligrotug Trial for Thyroid Eye Disease
Viridian Therapeutics Meets Endpoints in Late-Stage Veligrotug Trial for Thyroid Eye Disease
Dec 16, 2024
09:10 AM EST, 12/16/2024 (MT Newswires) -- Viridian Therapeutics ( VRDN ) said Monday that a late-stage trial of candidate drug veligrotug met all of its primary and secondary endpoints for symptoms of chronic thyroid eye disease. Viridian said about 56% of the trial's veligrotug-treated patients experienced a reduction in proptosis or the abnormal bulging of eyes, with a 2.34...
HeartBeam's Heart Monitoring Device Receives US FDA Clearance
HeartBeam's Heart Monitoring Device Receives US FDA Clearance
Dec 16, 2024
09:07 AM EST, 12/16/2024 (MT Newswires) -- HeartBeam ( BEAT ) said Monday its HeartBeam ( BEAT ) device has received 510(k) clearance from the US Food and Drug Administration for comprehensive arrhythmia assessment. The device tracks heart signals from three directions to provide heart health information, the company said. Shares of HeartBeam ( BEAT ) were up more than...
Honeywell Considers Separation of Aerospace Business as Part of Portfolio Optimization Efforts
Honeywell Considers Separation of Aerospace Business as Part of Portfolio Optimization Efforts
Dec 16, 2024
09:08 AM EST, 12/16/2024 (MT Newswires) -- Honeywell International ( HON ) on Monday said it is evaluating a potential separation of its aerospace business as part of the industrial conglomerate's efforts to optimize its portfolio. The company said its board of directors continues to explore strategic alternatives to unlock shareholder value and has made significant progress so far. Honeywell...
Copyright 2023-2026 - www.financetom.com All Rights Reserved